Ligand Pharmaceuticals Inc. news

   Watch this stock
Showing stories 1 - 10 of about 94   

Articles published

LGND 49.14 -2.31 (-4.49%)
price chart
Ligand Pharmaceuticals is Now Oversold (LGND)
In trading on Wednesday, shares of Ligand Pharmaceuticals Inc (NASD: LGND) entered into oversold territory, hitting an RSI reading of 27.7, after changing hands as low as $52.87 per share.
Related articles »  
Lemeson Ups Ligand Pharmaceuticals Inc. (LGND) Short
Lemelson Capital Management, a private investment management firm, today announced that it has further increased its short position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and appended with additional concerns its initial June 16, 2014 research ...
Ligand Pharmaceuticals: Appendix  Seeking Alpha
Related articles »  
Biotech Insider Buying: bluebird bio (NASDAQ:BLUE), Ligand Pharmaceuticals ...
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Chief Operating Officer & Executive Vice President Matthew W. Foehr acquired 428shares of bluebird bio stock in a transaction that occurred on Monday, June 30.
Ligand Reports Second Quarter Revenues and Announces Share Repurchase ...
"We are pleased with the financial performance of all aspects of our business and to be reporting second quarter revenues that are meaningfully above our previous guidance," said Nishan de Silva, Chief Financial Officer of Ligand Pharmaceuticals, Inc ...
Ligand Pharmaceuticals Inc.: Ligand Signs Global License Agreement with TG ...
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced the signing of an exclusive global license agreement with TG Therapeutics, Inc. (NASDAQ: TGTX) for the development and commercialization of Ligand's ...
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog  NASDAQ
TG Therapeutics Completes Global Licensing Agreement With Ligand ...  GlobeNewswire (press release)
Related articles »  
Ligand Pharmaceuticals Inc.: Ligand Chairman Dr. John W. Kozarich Named ...
Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly & Co. and Spectrum ...
Related articles »  
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors
According to the deal, Ligand Pharma will receive 125,000 unregistered shares of TG Therapeutics' common stock, valued at about $1 million on the date of signing the deal.
Biotech Decliners: ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Ligand ...
... Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that Chairman John W. Kozarich Ph.D. has been named by Corporate Directors Forum as one of six Directors of the Year for 2014.
Related articles »  
Ligand Pharmaceuticals (LGND): Lemelson Reaffirms 0 PT
Marlborough, MA, June 24, 2014 - Lemelson Capital Management, a private investment management firm, today reaffirmed the analysis presented in its 25-page research report on Ligand Pharmaceuticals Inc. (NASDAQ:LGND), released originally on June ...
Related articles »  
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7%
Ligand Pharmaceuticals Incorporated (LGND - Snapshot Report) saw a big move last session, as the company's shares fell by nearly 7% on the day.
Related articles »